UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 165

of 'Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis'

165
TI
[Effect of secretin and gabexate-mesilate (synthetic protease inhibitor) on serum amylase level after ERCP].
AU
Tympner F, Rösch W
SO
Z Gastroenterol. 1982;20(11):688.
 
Complication rate of ERCP is about 2%, mortality rate 0,2%. In about 1% acute pancreatitis or recurrency of chronic pancreatitis occurs. In 20 to 73% a rise of serum amylase is noted without clinical symptoms. In a randomized trial the influence of secretin and gabexate-mesilate (synthetic protease inhibitor) on ERCP-correlated complications was analyzed. Gabexate-mesilate caused a significant decrease of ERCP-induced hyperamylasemias, whereas secretin showed no effect.
AD
PMID